The Safety of Continuous Infusion Propofol in Mechanically Ventilated Adults With Coronavirus Disease 2019

Corey J. Witenko, PharmD, BCPS, BCCCP, Audrey J. Littlefield, PharmD, BCPS, BCCCP, Sajjad Abedian, MS, Anjile An, MPH, Philip S. Barie, MD, MBA, MAMSE, MCCM, and Karen Berger, PharmD, BCPS, BCCCP

Abstract
Background: Propofol is commonly used to achieve ventilator synchrony in critically ill patients with coronavirus disease 2019 (COVID-19), yet its safety in this patient population is unknown. Objective: To evaluate the safety, in particular the incidence of hypertriglyceridemia, of continuous infusion propofol in patients with COVID-19. Methods: This was a retrospective study at 1 academic medical center and 1 affiliated teaching hospital in New York City. Adult, critically ill patients with COVID-19 who received continuous infusion propofol were included. Patients who received propofol for <12 hours, were transferred from an outside hospital while on mechanical ventilation, or did not have a triglyceride concentration obtained during the infusion were excluded. Results: A total of 252 patients were included. Hypertriglyceridemia (serum triglyceride concentration ≥ 400 mg/dL) occurred in 38.9% of patients after a median cumulative dose of 4307 mg (interquartile range [IQR], 2448-9431 mg). The median time to triglyceride elevation was 3.8 days (IQR, 1.9-9.1 days). In the multivariable regression analysis, obese patients had a significantly greater odds of hypertriglyceridemia (odds ratio = 1.87; 95% CI = 1.10, 3.21). There was no occurrence of acute pancreatitis. The incidence of possible propofol-related infusion syndrome was 3.2%. Conclusion and Relevance: Hypertriglyceridemia occurred frequently in patients with COVID-19 who received propofol but did not lead to acute pancreatitis. Elevated triglyceride concentrations occurred more often and at lower cumulative doses than previously reported in patients without COVID-19. Application of these data may aid in optimal monitoring for serious adverse effects of propofol in patients with COVID-19.

Keywords
sedatives, pancreatitis, adverse drug reactions, respiratory failure, critical care

Introduction
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization in March 2020. In the ongoing global crisis, it has been estimated that 15% to 20% of cases require hospitalization and 3% to 5% require intensive care. Depending on definitions used and the degree of surging conditions, substantial worldwide variability has been reported with respect to the need for mechanical ventilation and outcomes of COVID-19–related critical illness. Data from Atlanta, Georgia at the onset of the pandemic suggested that 76% of critically ill patients required mechanical ventilation, with a mortality rate of 36%. By contrast, in 2 contemporaneous reports from metropolitan New York City, including the authors’ own institution, the need for critical care was estimated at 14%, the need for mechanical ventilation from 12% to 33%, and the mortality rate from 10% to 21%.

Respiratory failure from COVID-19 is often severe and protracted; patients requiring mechanical ventilation often...
require prolonged, deep sedation to optimize oxygenation and ventilation and facilitate ventilator synchrony. In the general critical care population, guidelines recommend use of nonbenzodiazepine sedatives, such as propofol or dexmedetomidine, as first-line remedies to improve short-term outcomes.\(^5\)\(^6\) However, patients with COVID-19 often require high doses of sedative medications for prolonged periods, and propofol is integral to achieving these goals.\(^7\)\(^8\)

Propofol, an anesthetic agent formulated in a 10% lipid emulsion, has a favorable pharmacokinetic profile with a rapid onset and short duration of action.\(^5\) Possible adverse effects of propofol administration include respiratory depression, hypotension, hypertriglyceridemia, and propofol-related infusion syndrome (PRIS). Hypertriglyceridemia, in turn, can be associated with acute pancreatitis,\(^9\)\(^10\) which can be severe. The risk of acute pancreatitis is increased with triglyceride concentrations >500 mg/dL, and the risk is significantly higher with triglyceride concentrations >1000 mg/dL.\(^11\) As a result, many clinicians monitor triglyceride concentrations every 2 to 3 days during prolonged infusion and may switch to an alternative sedative agent if the concentration exceeds 400 to 500 mg/dL. These alternative agents are typically benzodiazepines, which have been associated with worse outcomes, such as increased delirium, longer duration of mechanical ventilation, and longer ICU and hospital lengths of stay.\(^5\)\(^12\) PRIS is a rare, potentially devastating complication associated with prolonged high doses (>83 µg/kg/min for >48 hours), and has a reported mortality rate ranging from 18% to 48%.\(^13\)\(^15\)

Clinical features of PRIS may include refractory bradycardia, metabolic acidosis, hyperkalemia, rhabdomyolysis, hyperlipidemia, acute kidney injury, or acute fatty liver.\(^16\) Finally, there is a potential risk of hypertriglyceridemia from propofol use in patients who develop secondary hemophagocytic lymphohistiocytosis (sHLH), a macrophage activation syndrome that, similar to COVID-19, can be associated with cytokine storm.\(^17\) Patients with sHLH may have elevated triglyceride concentrations at baseline.\(^18\)\(^19\)

The objective of this study was to assess the safety of continuous infusion propofol in mechanically ventilated critically ill patients with COVID-19. We examined the incidences of hypertriglyceridemia, acute pancreatitis, PRIS, and propofol reduction or discontinuation caused by adverse effects. We hypothesized that hypertriglyceridemia is more prevalent among these patients and occurs at lower cumulative doses of the drug.

**Materials and Methods**

This was a retrospective study of adult patients admitted to an intensive care unit (ICU) at an academic medical center, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and an affiliated teaching hospital, NewYork-Presbyterian/Lower Manhattan Hospital, between March 1, 2020, and April 30, 2020. Patients with a positive nasopharyngeal swab for SARS-CoV-2 by reverse transcriptase-polymerase chain reaction test and who received continuous infusion propofol for at least 12 hours were included. Patients were excluded if they received propofol for <12 hours, did not have a triglyceride concentration measured during propofol administration, or were transferred from an outside hospital already supported by mechanical ventilation. The study was approved by the Institutional Review Board of NewYork-Presbyterian Hospital/Weill Cornell Medical Center (20-05021995), with a waiver of informed consent. Patients were identified and relevant clinical parameters were obtained from electronic health records (EHRs) using the COVID-19 Institutional Data Repository (IDR). Data abstraction was completed on August 15, 2020. COVID IDR is a resource created and maintained by NewYork-Presbyterian Hospital and Weill Cornell Medicine, which brings together clinical and research information from disparate sources, including both ambulatory and inpatient EHR systems.\(^20\)

The primary outcome was the incidence of hypertriglyceridemia defined as any triglyceride concentration of ≥400 mg/dL after propofol initiation. Additionally, we characterized the relationships among triglyceride concentrations and propofol dose and duration, the need for vasopressor therapy within 6 hours of propofol initiation, and the incidences of acute pancreatitis and possible PRIS. In patients with hypertriglyceridemia, the incidences of propofol infusion rate reduction and discontinuation were recorded, along with addition of adjunctive or alternative agents within 24 hours of dose reduction/discontinuation. A reduction in propofol rate was considered clinically meaningful if the reduction was by at least 20 µg/kg/min or at least 50% lower than the rate when hypertriglyceridemia was discovered. Adjunctive or alternative agents included chloridiazepoxide, diazepam, lorazepam, midazolam, dexmedetomidine, olanzapine, quetiapine, oxycodone, and methadone. Acute pancreatitis was defined as elevated pancreatic enzymes in serum (eg, amylase, lipase) and abdominal computed tomography with findings consistent with acute pancreatitis (eg, pancreatic edema or infarction, peripancreatic fluid collection[s]).\(^21\)\(^23\)

Elevated pancreatic enzymes were defined as a serum amylase concentration ≥125 IU/L or serum lipase concentration ≥60 IU/L.

All patients with an elevated creatinine kinase (CK) concentration (≥5000 U/L) were evaluated for PRIS. Given that myositis is a clinical feature of COVID-19,\(^24\) the lack of diagnostic specificity, the nonspecific clinical presentation of PRIS, and lack of a standard definition,\(^14\)\(^15\) patients were considered to have “possible” PRIS if they had an elevated CK concentration and at least 2 of the following while receiving propofol: anion gap metabolic acidosis, serum lactate concentration ≥4 mmol/L, serum potassium concentration ≥5.5 mEq/L, acute bradyarrhythmia or cardiovascular...
collapse, acute kidney injury, or elevated concentrations of liver enzymes. Acute bradyarrhythmia was defined as a new drop in heart rate to less than 60 beats per minute not in sinus rhythm, and cardiovascular collapse included cardiac failure in the absence of cardiac disease. Acute kidney injury was defined as an elevation of serum creatinine greater than 50% from baseline or at least 0.3 mg/dL. Elevated liver enzymes were defined as an increase in concentrations to at least 3 times the upper limit of normal. Patients met the definition for possible PRIS if they had at least 2 of the listed criteria within 24 hours of elevated CK concentration. All laboratory monitoring, including triglyceride and CK concentrations, were obtained at the discretion of the provider.

Descriptive statistics were used to characterize the study sample with respect to demographic and clinical factors of interest. Continuous variables are represented as median (interquartile range [IQR]), and categorical variables are represented as n (%). Where appropriate, the χ² test (or the Fisher exact test) and the Wilcoxon rank-sum test were used to examine the association between demographic/clinical factors of interest and the presence of hypertriglyceridemia. Statistically significant variables identified by univariate analysis (P < 0.10) were included in a multivariable logistic regression model to evaluate their independent effect on hypertriglyceridemia risk. Adjusted odds ratios (ORs) and 95% CIs for the risk/protective factors of interest were estimated from the multivariable model. All P values are 2-sided, with statistical significance evaluated at the 0.05 α level. All analyses were performed in R Version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria).

**Results**

A total of 311 consecutive patients met inclusion criteria during the defined time period (Figure 1). In all, 59 patients were excluded as a result of either propofol administration for <12 hours, no serum triglyceride concentration measured, or transfer from an outside hospital while on mechanical ventilation. The 252 patients included in the primary analysis were mostly male (71.8%), with a median age of 67 years (IQR, 58-74 years; Table 1). No patient received parenteral nutrition support during propofol infusion. The cohort had high acuity, with a median Acute Physiology and Chronic Health Evaluation (APACHE) II score of 27 (IQR, 22-31) and Sequential Organ Failure Assessment score of 12 (IQR, 10-13). The median ICU and hospital lengths of stay were 33 days (IQR, 16.8-60.3 days) and 38 days (IQR, 20-62.2 days), respectively. The mortality rate was 32.5%, and the majority of survivors were discharged to a medical facility.

Hypertriglyceridemia occurred in 98 patients (38.9%) who received continuous infusion propofol (Table 2). The median time to elevated triglycerides was 3.8 days (IQR, 1.9-9.1 days), and the median total dose was 4307 mg
Only 2.8% of patients had a serum triglyceride concentration ≥ 1000 mg/dL, which occurred at a median of 9.9 days (IQR, 7.9-19.7 days) from propofol initiation. The median infusion rate at the time hypertriglyceridemia was detected was 50 µg/kg/min (IQR, 40-60 µg/kg/min), and the incidences of decreasing or discontinuing the infusion within 24 hours were 35.7% and 16.3%, respectively. Adjunctive or alternative sedative agents were initiated in 26.5% of patients (eg, midazolam 46.1%, lorazepam 27%). Hypotension requiring vasopressor support within 6 hours after propofol initiation occurred in 11.1% of patients.

**Table 1. Demographic and Baseline Characteristics.**

| Characteristic                                      | n = 252          |
|-----------------------------------------------------|------------------|
| Age, years, median [IQR]                            | 67 [58, 74]      |
| Sex, n (%)                                          |                  |
| Female                                              | 71 (28.2)        |
| Male                                                | 181 (71.8)       |
| Ethnicity, n (%)                                    |                  |
| African American                                    | 22 (8.7)         |
| Asian                                               | 47 (18.7)        |
| White                                               | 69 (27.4)        |
| Other/multiracial                                   | 49 (19.4)        |
| Unknown                                             | 65 (25.8)        |
| Weight, kg, median [IQR]                            | 80.2 [69.0, 94.1]|
| BMI, n (%)                                          |                  |
| BMI < 30 kg/m²                                       | 151 (60.2)       |
| BMI ≥ 30 kg/m²                                       | 100 (39.8)       |
| Past medical history, n (%)                         |                  |
| Chronic obstructive pulmonary disease               | 28 (11.1)        |
| Asthma                                              | 41 (16.3)        |
| Coronary artery disease                             | 65 (25.8)        |
| Chronic congestive heart failure                    | 11 (4.4)         |
| Never smoker\(^b\)                                  | 82 (59.9)        |
| Diabetes type 1                                      | 7 (2.8)          |
| Diabetes type 2                                      | 133 (52.8)       |
| Hyperlipidemia                                       | 23 (9.1)         |
| Hypertension                                         | 193 (76.6)       |
| Chronic kidney disease                              | 73 (29)          |
| End-stage renal disease                             | 34 (13.5)        |
| Liver disease                                        | 9 (3.6)          |
| APACHE II score, median [IQR]                       | 27 [22, 31]      |
| SOFA score, median [IQR]                            | 12 [10, 13]      |
| Vasopressor support (≥ 12 hours), n (%)             | 204 (81)         |
| Mechanical ventilation duration, days, median [IQR]  | 21 [12, 45]      |
| New renal replacement therapy, n (%)                | 20 (7.9)         |
| Bacteremia, n (%)                                   | 53 (21)          |
| Candidemia, n (%)                                   | 6 (2.4)          |
| ICU length of stay, days, median [IQR]\(^c\)        | 33 [16.8, 60.3]  |
| Hospital length of stay, days, median [IQR]         | 38 [20, 62.2]    |
| Discharge disposition, n (%)                         |                  |
| Hospital mortality                                  | 82 (32.5)        |
| Discharge home                                       | 56 (22.2)        |
| Facility                                             | 109 (43.3)       |
| Still in hospital                                    | 5 (2.0)          |

**Abbreviations:** APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index; ICU, intensive care unit; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment.

\(^a\) n = 251 Patients with documented height.

\(^b\) n = 137 Patients had a smoking status.

\(^c\) n = 247 Patients because 5 were hospitalized at the time the date was finalized.
### Table 2. Propofol Administration and Serum Triglyceride Concentrations.

| Characteristic                                                                 | n = 252 |
|-------------------------------------------------------------------------------|---------|
| TG $\geq$ 400, mg/dL, n (%)                                                  | 98 (38.9) |
| Time to TG $\geq$ 400 from propofol initiation, days, median [IQR]$^a$      | 3.8 [1.9, 9.1] |
| TG $\geq$ 1000, mg/dL, n (%)                                                 | 7 (2.8) |
| Time to TG $\geq$ 1000 from propofol initiation, days, median [IQR]$^b$     | 9.9 [7.9, 19.7] |
| Patients with $\geq$ 2 TG concentrations$^c$                                |         |
| Initial TG after propofol initiation, median [IQR]                            | 202 [138, 271] |
| Time to initial TG after propofol initiation, days, median [IQR]              | 1.3 [0.4, 2.5] |
| Maximum TG, mg/dL, median [IQR]                                               | 348 [239, 510] |
| Maximum increase in TG from initial TG, mg/dL, median [IQR]                   | 115 [52, 271] |
| Time to maximum TG after propofol start, days, median [IQR]                   | 8 [4.4, 14.3] |
| Any vasopressor initiation within 6 hours after propofol initiation, n (%)$^d$| 28 (11.1) |
| Norepinephrine                                                               | 23 (9.1) |
| Vasopressin                                                                  | 6 (2.4) |
| Phenylephrine                                                                | 26 (10.3) |
| Any pancreatic enzyme concentrations obtained, n (%)                         | 103 (40.9) |
| Amylase obtained, n (%)                                                       | 37 (14.7) |
| Lipase obtained, n (%)                                                        | 103 (40.9) |
| Among those with pancreatic enzyme concentrations obtained                    |         |
| Any elevated pancreatic enzyme concentration, n (%)$^e$                     | 61 (59.2) |
| Elevated amylase, n (%)                                                       | 15 (40.5) |
| Elevated lipase, n (%)                                                        | 60 (58.3) |
| Acute pancreatitis confirmed with radiographic imaging$^h$                    | 0       |
| Possible PRIS, n (%)                                                          | 8 (3.2) |
| No CK, n (%)                                                                  | 6 (2.4) |

Abbreviations: CK, creatinine kinase; IQR, interquartile range; PRIS, propofol-related infusion syndrome; TG, triglycerides.

$^a$ n = 98.

$^b$ n = 7.

$^c$ n = 172, Excluding patients if initial triglyceride level was maximum.

$^d$ Epinephrine, dopamine, and angiotensin II were not initiated.

$^e$ n = 103.

$^f$ n = 37.

$^g$ n = 103.

$^h$ n = 12.

### Table 3. Propofol Administration at the Time of Hypertriglyceridemia.$^a$

| Characteristic                                                                 | n = 98 |
|-------------------------------------------------------------------------------|---------|
| Cumulative propofol dose, mg, median [IQR]                                    | 4307 [2448, 9431] |
| Dose of propofol, µg/kg/min, median [IQR]                                     | 50 [40, 60] |
| Propofol discontinued within 24 hours, n (%)                                  | 16 (16.3) |
| Propofol decrease by $\geq$ 20 µg/kg/min or by 50% within 24 hours, n (%)    | 35 (25.7) |
| Propofol decreased by $\geq$ 20 µg/kg/min within 24 hours, n (%)             | 27 (27.6) |
| Decrease of propofol by 50% within 24 hours, n (%)                           | 30 (30.6) |
| Addition of adjunctive/alternative agent within 24 hours, n (%)$^b$          | 26 (26.5) |
| Midazolam                                                                    | 12 (46.1) |
| Lorazepam                                                                    | 7 (27) |
| Dexmedetomidine                                                               | 2 (7.7) |
| Quetiapine                                                                   | 3 (11.5) |
| Olanzapine                                                                   | 1 (3.8) |
| Oxycodone                                                                    | 1 (3.8) |

Abbreviation: IQR, interquartile range.

$^a$ All parameters pertain to the time of initial triglyceride $\geq$ 400 mg/dL.

$^b$ No patient had more than 1 agent initiated. Diazepam, chlordiazepoxide, and methadone were not initiated.
Comparing patients with or without hypertriglyceridemia, both groups had similar severity of illness, history of hyperlipidemia on admission, and hospital length of stay (Table 4), but there was a relationship between body mass index (BMI) and development of hypertriglyceridemia ($P = 0.015$), with a greater proportion of obese (BMI $\geq 30$ kg/m$^2$) patients in the hypertriglyceridemia group. Although likely statistical coincidence, there was a significant relationship between discharge disposition and development of hypertriglyceridemia ($P = 0.042$), with more patients discharged home in the hypertriglyceridemia group. Although cumulative propofol dose, duration, and time to peak triglyceride concentrations were similar, patients with hypertriglyceridemia had a longer duration of high-dose propofol administration ($\geq 50$ µg/kg/min; $3.9$ vs $3.0$ days, $P = 0.036$).

Pancreatic enzymes were not assessed routinely during propofol administration, but 61 (59.2%) patients had elevated concentrations when obtained. Providers checked pancreatic enzyme concentrations more frequently in those who developed hypertriglyceridemia (amylase: $23.5\%$ vs $9.1\%$, $P = 0.003$; lipase: $53.1\%$ vs $33.1\%$, $P = 0.003$). However, there was no difference in the incidence of elevated pancreatic enzyme concentrations. Although only 12 (19.7%) patients with elevated concentrations had imaging performed, there was no clinical or radiographic evidence of acute pancreatitis in any patient.

CK was checked frequently (at least once for $97.6\%$ of patients), and 8 (3.2%) patients met our definition of possible PRIS, 4 of whom had hypertriglyceridemia. Six (75%) patients met at least 4 of our PRIS criteria in addition to CK $\geq 5000$ U/L. The duration of propofol administration prior to CK elevation ranged from 2 to 17 days, and 5 (62.5%) patients received doses $\geq 40$ µg/kg/min for $>48$ hours. Two patients (25%) died within 7 days of the identified CK elevation. There was no association of hypertriglyceridemia and possible PRIS.

A multivariable logistic regression model with BMI, duration of propofol $\geq 50$ µg/kg/min, and duration of propofol infusion showed that obese patients independently had 1.87 times the odds of developing hypertriglyceridemia compared with nonobese patients, adjusting for propofol dose and duration of propofol dose $\geq 50$ µg/kg/min (95% CI: 1.10, 3.21; Table 5).

**Discussion**

This is the largest study evaluating propofol use and safety in patients with COVID-19 and, to our knowledge, is also the largest study to date assessing the incidence of hypertriglyceridemia caused by propofol in a real-world setting. Given that patients with COVID-19 often have deeper sedation targets to facilitate comfort and ventilator synchrony during long-duration mechanical ventilation, it is important to elucidate the safety profile of propofol in this patient population.

Propofol is formulated in a phospholipid emulsion and may lead to hypertriglyceridemia with high doses or long-duration use. Elevated triglycerides in patients on propofol therapy have been associated with adverse sequelae, including acute pancreatitis. Although the evidence characterizing the relationship of hypertriglyceridemia and acute pancreatitis is scant, many clinicians use a triglyceride concentration of 400 to 500 mg/dL as a cutoff for using alternative or sedative agents. Guidelines recommend monitoring triglyceride concentrations after 2 days of propofol infusion but not a threshold to prompt dose reduction or discontinuation. Interestingly, subsequent guidelines omit similar recommendations and do not provide further insight.

A 2005 retrospective cohort study found that 18% of patients on propofol therapy had elevated triglycerides of $\geq 400$ mg/dL, and 4% of patients had a concentration $\geq 1000$ mg/dL. The incidence of hypertriglyceridemia-associated pancreatitis in the cohort was $1.9\%$. By comparison, the incidence of hypertriglyceridemia in our study was 38.9%, double the rate described by Devlin et al. Patients in our study were more critically ill (median APACHE II score, 27 vs 19) and had a longer ICU length of stay (33 vs 8.6 days). The propofol infusion rate upon hypertriglyceridemia diagnosis was similar at 50 µg/kg/min, but the cumulative dose at that time was substantially lower in our cohort (4307 vs 15 032 mg). Data on obesity, metabolic syndrome, and baseline triglyceride levels were not described in the study by Devlin et al, making it unclear if these contributed to the differences in hypertriglyceridemia seen in our cohort. Despite this, our data suggest that COVID-19 may lead to the development of hypertriglyceridemia more often and at lower cumulative doses, without an increased risk of acute pancreatitis.

A recent study at the same institution found that 27.9% of patients developed triglyceride concentrations $\geq 400$ mg/dL while on propofol, with a 1.5% incidence of acute pancreatitis. In this study, patients developed hypertriglyceridemia after a median of 47 hours (IQR, 16.3-73.5 hours) and received a median cumulative propofol dose of 21 800 mg (IQR, 9300-32 400 mg). This contrasts with our study because patients developed hypertriglyceridemia after a median of 3.8 days and received a median cumulative propofol dose of 11 700 mg in our cohort. The higher incidence of hypertriglyceridemia at lower cumulative doses suggests that COVID-19 may have an impact on the metabolism and utilization of triglycerides.

One small prospective observational study to date has compared propofol-associated hypertriglyceridemia in patients with and without COVID-19. Over a 7-day study period, the authors found that patients with COVID-19 had a higher incidence of triglyceride concentrations $>500$ mg/
Table 4. Propofol Comparison With and Without Hypertriglyceridemia.

| Characteristic                              | All patients, n = 252 | Hypertriglyceridemia (TG ≥ 400), n = 98 | No hypertriglyceridemia, n = 154 | P  |
|---------------------------------------------|------------------------|------------------------------------------|----------------------------------|----|
| APACHE II, median [IQR]                     | 27 [22, 31]            | 26 [21, 30]                              | 27 [23, 31]                      | 0.16|
| SOFA score, median [IQR]                    | 12 [10, 13]            | 11.5 [10.2, 13.0]                        | 12 [10, 13]                      | 0.79|
| History of hyperlipidemia, n (%)            | 23 (9.1)               | 6 (6.1)                                  | 17 (11)                         | 0.27|
| BMI, n (%)                                  |                        |                                          |                                  | 0.015|
| BMI < 30 kg/m²                               | 151 (60.2)             | 49 (50)                                  | 102 (66.7)                      |
| BMI ≥ 30 kg/m²                               | 100 (39.8)             | 49 (50)                                  | 51 (33.3)                       |
| Hospital length of stay, days, median [IQR] | 38 [20, 62]            | 42.5 [23.0, 67.5]                       | 35 [18, 59]                      | 0.063|
| Discharge disposition, n (%)                |                        |                                          |                                  | 0.042|
| Hospital mortality                          | 82 (32.5)              | 30 (30.6)                                | 52 (33.8)                       |
| Discharge home                               | 56 (22.2)              | 28 (28.6)                                | 28 (18.2)                       |
| Facility                                     | 109 (43.3)             | 36 (36.7)                                | 73 (47.4)                       |
| Still in hospital                           | 5 (2)                  | 4 (4.1)                                  | 1 (0.6)                         |
| Cumulative propofol dose, mg, median [IQR]  | 17 777 [5801, 17 025]  | 11 730 [6442, 17 324]                   | 9990 [5391, 16 732]             | 0.30|
| Duration of propofol infusion, days, median [IQR] | 17.9 [9.1, 27.0]         | 18.5 [11.2, 31.3]                        | 16.7 [8.5, 25.6]                | 0.071|
| Peak TG after propofol initiation, mg/dL, median [IQR] | 336 [224, 502]          | 563 [466, 761]                           | 244 [182, 318]                  | <0.001|
| Time to peak TG after propofol initiation, days, median [IQR] | 5.8 [2.5, 10.8]         | 5.5 [2.6, 10.8]                         | 6 [2.4, 10.7]                   | 0.81|
| Duration of propofol dose ≥ 50 µg/kg/min, days, median [IQR] | 3.4 [1.4, 6.8]          | 3.9 [1.8, 7.6]                           | 3 [1.1, 6.4]                    | 0.036|
| Pancreatic enzyme concentrations, n (%)      |                        |                                          |                                  |     |
| Amylase obtained                            | 37 (14.6)              | 23 (23.5)                                | 14 (9.1)                        | 0.003|
| Amylase elevated                            | 15 (40.5)              | 11 (47.8)                                | 4 (28.6)                        | 0.42|
| Lipase obtained                             | 103 (40.9)             | 52 (53.1)                                | 51 (33.1)                       | 0.003|
| Lipase elevated                             | 60 (58.3)              | 31 (59.6)                                | 29 (56.9)                       | 0.93|
| Acute pancreatitis                          | 0                      | 0                                       | 0                                |
| Possible PRIS, n (%)                         | 8 (3.2)                | 4 (4.1)                                  | 4 (2.6)                         | 0.71|
| Tocilizumab, n (%)                           | 41 (16.3)              | 20 (20.4)                                | 21 (13.6)                       | 0.21|

Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index; IQR, interquartile range; PRIS, propofol-related infusion syndrome; SOFA, Sequential Organ Failure Assessment; TG, triglycerides.

* n = 251 Patients with documented height.
* n = 97.
* n = 140.
* n = 37.
* n = 23.
* n = 14.
* n = 103.
* n = 52.
* n = 5.
The triglyceride concentration alone should not be used as a monitoring parameter for PRIS because we could identify no correlation. This is consistent with a previous publication.6 Unfortunately, guidelines are silent as to recommendations for monitoring and treatment of PRIS.6 However, because of the prolonged, high doses of propofol administered to COVID-19 patients, providers should be mindful of the clinical manifestations of PRIS and the overlap with known COVID-19 manifestations and can monitor CK often to facilitate recognition and minimize morbidity.

There are other potential risks of using propofol in patients with COVID-19, specifically those who develop sHLH-like cytokine storm, because they may have elevated triglycerides at baseline.18,19 sHLH and COVID-19 critical illness can manifest similarly, possibly exacerbating the risk of propofol-related hypertriglyceridemia.33 A recent cross-sectional study demonstrated that high triglyceride concentrations were strong predictors of a severe course of COVID-19.34 The pathophysiology involves the overexpression of cytokines, and the inflammatory state produced during COVID-19 infection leads to significant changes in lipid metabolism, specifically affecting the lipoprotein lipase enzyme.34 This decreased enzyme activity results in decreased conversion of triglyceride-rich lipoproteins to low-density lipoprotein, which ultimately results in elevated triglycerides and decreased high-density lipoprotein concentrations.14 Another recent study described the dysregulation of lipid metabolism in patients with COVID-19.35 The authors found that patients with severe COVID-19 disease were more likely to have alterations in serum concentrations of lipids, including triglycerides, than those with mild or moderate disease.35 This has been described in other viral infections,36 and altered lipid metabolism ultimately leads to alterations in mitochondria homeostasis and energy production.35

One study37 that characterized patients with COVID-19 who received the interleukin-6 receptor antagonist tocilizumab38 for cytokine storm found that 29 patients (35.8%) experienced hypertriglyceridemia >500 mg/dL, and of those patients, 8 (27.6%) did not receive propofol. Tocilizumab-related hypertriglyceridemia has not been reported previously. In our cohort, only 16.3% of patients received tocilizumab, and there was no difference in the development of hypertriglyceridemia in these patients. When all these data are considered, it is evident that there are multiple mechanisms that may lead to elevated

---

**Table 5. Multivariable Logistic Regression.**

| Characteristic                      | OR  | 95% CI     | P     |
|------------------------------------|-----|------------|-------|
| **BMI ≥ 30 kg/m²**                 | 1.87| 1.10, 3.21 | 0.022 |
| Duration of propofol dose ≥50 µg/kg/min (d) | 1.05| 0.98, 1.12 | 0.18  |
| Duration of propofol infusion (days) | 1.01| 0.99, 1.03 | 0.18  |

Abbreviations: BMI, body mass index; OR, odds ratio.
triglycerides in patients with severe COVID-19. Given the retrospective nature of this study, the exact causes of hypertriglyceridemia seen in patients with COVID-19 are uncertain and cannot be solely attributed to propofol administration.

Based on this study, we offer several recommendations and considerations regarding the safety of propofol use in COVID-19. First, monitor triglyceride concentrations within 2 to 3 days of propofol initiation and every 2 to 3 days, especially for obese patients and those receiving high-dose propofol infusions. Second, a triglyceride threshold of 400 to 500 mg/dL to discontinue propofol may be liberalized given the low risk of acute pancreatitis seen in this cohort as well as other published studies.9,10 Third, consider obtaining CK concentrations every 2 to 3 days to monitor for PRIS, especially for prolonged, high-dose propofol infusions.

This study has several limitations, including its retrospective nature, which render our observations speculative. Most of the data were pulled from an IDR, which raises the possibility that the results may be confounded by missing data. However, data elements in question were reviewed manually to ensure accuracy as far as possible. For example, missing data points may have caused the APACHE II scores to be underestimated. Although implausible, there is a possibility of falsely elevated triglyceride concentrations if any blood specimens were obtained via blood specimen collection utilizing the infusion port assigned to propofol. Such an event is unlikely to be documented, although no specimens were noted to be grossly lipemic. Unfortunately, because of the retrospective design and difficulty obtaining an accurate medication history, lipid pharmacotherapy was not reported in these data. It is our policy to maintain home medications while admitted unless contraindicated. In response to the pandemic, our health system expanded ICU capacity substantially into alternative physical locations that utilized health care personnel with minimal formal critical care training.39-41 Substantial effort was made to standardize protocols and communication among permanent and temporary ICUs.39,42 However, sedation practices, propofol utilization, and monitoring (eg, triglycerides, CK) varied among units, which may have led to selection bias as to laboratory monitoring. For example, 27 patients who were excluded from our analysis received propofol for a median 3.6 days but never had monitoring of triglyceride concentration. Further highlighting the need for education on the monitoring and toxicity of propofol, only 6 patients had a baseline triglyceride concentration drawn before propofol administration. Therefore, it is difficult to assess the direct impact of propofol on triglyceride concentrations. It is plausible that patients with severe COVID-19 have a higher risk for hypertriglyceridemia at baseline,8,34,35 and propofol administration may accentuate this risk. Moreover, only 12 (19.7%) patients with elevated pancreatic enzymes had follow-up imaging to assess the pancreas. Thus, the overall rate of acute pancreatitis may not be zero. Finally, some patients had propofol discontinued and restarted multiple times throughout their admission; quantified cumulative exposure may be inaccurate.

**Conclusion and Relevance**

Hypertriglyceridemia occurred frequently in patients with COVID-19 critical illness who received continuous infusion propofol but did not lead to the development of acute pancreatitis. The only identified predisposing factor for hypertriglyceridemia was obesity. Elevated triglyceride concentrations occurred more often and at lower cumulative doses than reported previously in patients without COVID-19. PRIS was rare and challenging to diagnose but must be monitored carefully to aid in prompt recognition and intervention. Application of these data may aid in optimal monitoring for serious adverse effects of propofol used in patients with COVID-19.

**Declaration of Conflicting Interests**

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Barie has received honoraria for consulting from AKPA America, Entasis, Pfizer, Portola (now Alexion), and Tetraphase (now LaJolla). The remaining authors have disclosed that they do not have any conflicts of interest.

**Funding**

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study received support from NewYork-Presbyterian Hospital (NYPH) and Weill Cornell Medical College (WCMC), including the Clinical and Translational Science Center (CTSC; UL1 TR000457) and Joint Clinical Trials Office (JCTO).

**ORCID iDs**

Sajjad Abedian https://orcid.org/0000-0002-0411-5185
Karen Berger https://orcid.org/0000-0003-3686-3468

**References**

1. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report-51. Published March 11, 2020. Accessed April 28, 2021. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_8
2. Auld SC, Caridi-Scheible M, Blum JM, et al; Emory COVID-19 Quality and Clinical Research Collaborative. ICU and ventilator mortality among critically ill adults with coronavirus disease 2019. Crit Care Med. 2020;48:e799-e804. doi:10.1097/CCM.0000000000004457
3. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382:2372-2374. doi:10.1056/NEJMc2010419
4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA*. 2020;323:2052-2059. doi:10.1001/jama.2020.6775

5. Barr J, Fraser GL, Puntillo K, et al; American College of Critical Care Medicine. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med*. 2013;41:263-306. doi:10.1097/CCM.0b013e3182783b72

6. Devlin JW, Skrobot B, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. *Crit Care Med*. 2018;46:e825-e873. doi:10.1097/CCM.0000000000003299

7. Hanidziar D, Bittner EA. Sedation of mechanically ventilated COVID-19 patients: challenges and special considerations. *Anesth Analg*. 2020;131:e40-e41. doi:10.1213/ANE.0000000000004887

8. Kanes MT, McSparron JJ, Marshall AD, Renius K, Hyzy RC. Propofol-associated hypertriglyceridemia in coronavirus disease 2019 versus noncoronavirus disease 2019 acute respiratory distress syndrome. *Crit Care Explor*. 2020;2:e0303. doi:10.1097/CCE.0000000000000303

9. Devlin JW, Lau AK, Tanios MA. Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. *Pharmacotherapy*. 2005;25:1348-1352. doi:10.1592/phco.2005.25.10.1348

10. Corrado MJ, Kovacevic MP, Dube KM, Lupi KE, Szumita PM, DeGrado JR. The incidence of propofol-induced hypertriglyceridemia and identification of associated risk factors. *Crit Care Explor*. 2020;2:e0282. doi:10.1097/CCE.0000000000002822

11. Murphy MJ, Sheng X, MacDonald TM, Wei L. Hypertriglyceridemia and acute pancreatitis. *JAMA Intern Med*. 2013;173:162-164. doi:10.1001/jama.2013.jamainternmed.477

12. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: The MENDS randomized controlled trial. *JAMA*. 2007;298:2644-2653. doi:10.1001/jama.298.22.2644

13. Fong JJ, Sylvia L, Ruthazer R, Schumaker G, Kcomt M, Devlin JW. Predictors of mortality in patients with suspected propofol infusion syndrome. *Crit Care Med*. 2008;36:2281-2287. doi:10.1097/CCM.0b013e318180c1eb

14. Roberts RJ, Barletta JF, Fong JJ, et al. Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. *Crit Care*. 2009;13:R169. doi:10.1186/cc8145

15. Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. *Br J Anesth*. 2019;122:448-459. doi:10.1016/j.bja.2018.12.025

16. Kam PCA, Cardone D. Propofol infusion syndrome. *Anaesthesia*. 2007;62:690-701. doi:10.1111/j.1365-2044.2007.05055.x

17. Soy M, Atagündüz P, Atagündüz İ, Sucak GT. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. *Rheumatol Int*. 2020;41:7-18. doi:10.1007/s00296-020-04636-y

18. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395:1033-1034. doi:10.1016/S0140-6736(20)30628-0

19. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. *Lancet*. 2014;383:1503-1516. doi:10.1016/S0140-6736(13)61048-X

20. Sholle ET, Kabariti J, Johnson SB, et al. Secondary use of patients’ electronic records (SUPER): an approach for meeting specific data needs of clinical and translational researchers. *AMIA Annu Symp Proc*. 2018;2017:1581-1588.

21. Crockett SD, Wani S, Gardner TB, Falek-Ytter Y, Barkun AN; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on initial management of acute pancreatitis. *Gastroenterology*. 2018;154:1096-1101. doi:10.1053/j.gastro.2018.01.032

22. Bollen TL. Acute pancreatitis: international classification and nomenclature. *Clin Radiol*. 2016;71:121-133. doi:10.1016/j.crad.2015.09.013

23. Thoeni RF. Imaging of acute pancreatitis. *Radiol Clin North Am*. 2015;53:1189-1208. doi:10.1016/j.rcl.2015.06.006

24. Zhang H, Charmchi Z, Seidman RJ, Anziska Y, Velayudhan V, Perk J. COVID-19-associated myositis with severe proximal and bulbar weakness. *Muscle Nerve*. 2020;62:E57-E60. doi:10.1002/mus.27003

25. Barie PS, Hyde LJ, Fischer E. Comparison of APACHE II and III scoring systems for mortality prediction in critical surgical illness. *Arch Surg*. 1995;130:77-82. doi:10.1001/archsurg.1995.0143001079016

26. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score-development, utility, and challenges of accurate assessment in clinical trials. *Crit Care*. 2019;23:374. doi:10.1186/s13054-019-2663-7

27. Jacobi J, Fraser GL, Coursin DB, et al; Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM); American Society of Health-System Pharmacists (ASHP); American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. *Crit Care Med*. 2002;30:119-141. doi:10.1097/00003246-200201000-00020

28. Barr J, Zomorodi K, Bertaccini EJ, Shafer SL, Geller E. A double-blind, randomized comparison of I.V. lorazepam vs. midazolam for sedation of ICU patients via a pharmacologic model. *Anesthesiology*. 2001;95:286-298. doi:10.1097/00000542-200108000-00007

29. Corbett SM, Montoya ID, Moore FA. Propofol-related infusion syndrome in intensive care patients. *Pharmacotherapy*. 2020;28:250-258. doi:10.1592/phco.28.2.250

30. Battie D, Soler MJ, Sparks MA, et al; COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group. Acute kidney injury in COVID-19: emerging evidence of a distinct
pathophysiology. *J Am Soc Nephrol.* 2020;31:1380-1383. doi:10.1681/ASN.2020040419

31. Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-related liver functional abnormality. *Clin Gastroenterol Hepatol.* 2020;18:1561-1566. doi:10.1016/j.cgh.2020.04.002

32. Schroeppe1 TJ, Fabian TC, Clement LP, et al. Propofol infusion syndrome: a lethal condition in critically injured patients eliminated by a simple screening protocol. *Injury.* 2014;45:245-249. doi:10.1016/j.injury.2013.05.004

33. Sherren PB, Ostermann M, Agarwal S, Meadows CIS, Ioannou N, Camporota L. COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review. *Br J Anesth.* 2020;125:912-925. doi:10.1016/j.bja.2020.08.050

34. Masana L, Correig E, Ibarretxe D, et al. Low HDL and high triglycerides predict COVID-19 severity. *Sci Rep.* 2021;11:7217. doi:10.1038/s41598-021-86747-5

35. Caterino M, Gelzo M, Sol S, et al. Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19. *Sci Rep.* 2021;11:2941. doi:10.1038/s41598-021-82426-7

36. Heaton NS, Randall G. Dengue virus-induced autophagy regulates lipid metabolism. *Cell Host Microbe.* 2010;8:422-432. doi:10.1016/j.chom.2010.10.006

37. Morrison AR, Johnson JM, Griebe KM, et al. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. *J Autoimmun.* 2020;114:102512. doi:10.1016/j.jaut.2020.102512

38. Crisafulli S, Isgrò V, La Corte L, Atzeni F, Trifirò G. Potential role of anti-interleukin (IL)-6 drugs in the treatment of COVID-19: rationale, clinical evidence, and risks. *BioDrugs.* 2020;34:415-422. doi:10.1007/s40259-020-00430-1

39. Barie PS, Bronstein M, Gibson CJ, et al. A simple three-tier classification system for triage, communication, and resource utilization by patients afflicted with COVID-19 disease. *Surg Infect (Larchmt).* 2020;21:726-727. doi:10.1089/sur.2020.146

40. Brickman D, Greenway A, Sobocinski K, et al. Rapid critical care training of nurses in the surge response to the coronavirus pandemic. *Am J Crit Care.* 2020;29:e104-e107. doi:10.4037/ajcc2020142

41. Peters AW, Chawla KS, Turnbull ZA. Transforming ORs into ICUs. *N Engl J Med.* 2020;382:e52. doi:10.1056/NEJMc2010853

42. Barie PS, Bronstein M, Gibson CJ, et al. A visual tool for enhanced critical care bedside communications during the coronavirus pandemic: the window wall of information. *Surg Infect (Larchmt).* 2020;21:817-818. doi:10.1089/sur.2020.148